Agile Therapeutics to Present at Women’s Health 2016: The 24th Annual Congress

PRINCETON, N.J., April 15, 2016 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products announced today that Dr. Elizabeth Garner, Chief Medical Officer will present on the topic of subject recruitment for the SECURE Phase 3 Study at Women’s Health 2016: The 24th Annual Congress in Washington, DC on April 17, 2016. 

The poster presentation, titled “Social Media and Text Messaging Outreach in the Recruitment of Millennials into a Phase 3 Contraceptive Patch Study” will discuss the impact of the use of social media to recruit young women to participate in the SECURE Study, a Phase 3 trial of the investigational contraceptive patch, Twirla^®.

The SECURE Study is a multicenter, single-arm, open-label Phase 3 clinical trial in which healthy women eighteen and over will receive treatment with the investigational patch for up to one year. The clinical trial will assess the effectiveness of the patch in preventing pregnancy using the Pearl Index as the primary contraceptive efficacy measure. Safety and tolerability will also be evaluated. Twirla contains the active ingredients ethinyl estradiol and levonorgestrel, both of which have an established history of efficacy and safety in currently marketed low-dose combination oral contraceptives. The patch is applied once weekly for three weeks followed by a patch-free week, and is designed to promote user compliance.

For more information, please visit http://www.academyofwomenshealth.org.

About Agile

Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate Twirla^® (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology called Skinfusion^®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability.  For more information, please visit the company website at www.agiletherapeutics.com.

Contact: Mary Coleman 609-683-1880